Back to Journals » International Journal of Nanomedicine » Volume 7

Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles

Authors Farazuddin, Bhavna, Khan AA, Beenu, Owais M

Received 7 August 2011

Accepted for publication 1 September 2011

Published 5 January 2012 Volume 2012:7 Pages 35—47


Review by Single anonymous peer review

Peer reviewer comments 4

Mohammad Farazuddin1, Bhawna Sharma2, Aijaz Ahmed Khan3, Beenu Joshi2, Mohammad Owais1
1Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, Uttar Pradesh, India; 2Immunology Division, NJIL and other Mycobacterial diseases, Agra-282001, Uttar Pradesh, India; 3Department of Anatomy, JN Medical college, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India

Abstract: In the present study, a novel poly-lactic glycolic acid (PLGA)-based microparticle formulation of perillyl alcohol (POH) was prepared and characterized. Further, its efficacy was evaluated against di-methyl benzo anthracene-induced skin papilloma in Swiss albino mice. The characterization studies showed that POH-bearing PLGA microparticles were of the size 768 ± 215 nm with a ζ-potential value of -7.56 ± 0.88 mV. The entrapment efficiency of the active drug in particles was 42.4% ± 3.5%. POH-bearing PLGA microparticles were stable and released entrapped drug gradually over an extended time period. The in vitro efficacy of POH-bearing PLGA microparticles was evaluated by examining their differential cytotoxicity and assessing their ability to inhibit epidermoid carcinoma cell line (A253). The POH-based microparticles when administered to tumor-bearing animals caused greater tumor regression and increased survival rate (~80%) as compared with the group receiving free form of POH (survival rate 40%). The superiority of POH-PLGA microparticles over free form of POH was further evident from their ability to modulate apoptosis-regulating factors.

Keywords: poly-lactic glycolic acid, epidermoid cancer cells, skin papilloma, anticancer efficacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]